Global Trends Today
  • News
  • Economy
  • Investing
  • Stock
  • Editor’s Pick
No Result
View All Result
  • News
  • Economy
  • Investing
  • Stock
  • Editor’s Pick
No Result
View All Result
Global Trends Today
No Result
View All Result
Home Editor's Pick

Hims & Hers Health says it will offer compounded GLP-1 injections

by
May 22, 2024
in Editor's Pick
0
Hims & Hers Health says it will offer compounded GLP-1 injections
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS
Previous Post

A new May high for the price of Ethereum at the $3839 level

Next Post

Hims & Hers Health says it will offer compounded GLP-1 injections

Next Post
Hims & Hers Health says it will offer compounded GLP-1 injections

Hims & Hers Health says it will offer compounded GLP-1 injections

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    • Trending
    • Comments
    • Latest

    Hacker lexicon: What is a supply chain attack?

    June 11, 2021

    Losing Depop to US ownership makes the British tech sector look secondhand

    June 11, 2021

    Andrew Lloyd Webber to sue the Government if theatres are not fully reopened from June 21

    June 11, 2021

    Microsoft’s Kate Crawford: ‘AI is neither artificial nor intelligent’

    June 11, 2021
    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    0

    Reply to “Reply to Whitehead” by Desvousges, Mathews and Train: (4) My treatment of the weighted WTP is biased in favor of the DMT (2015) result/conclusion

    0

    The 40 Weirdest (And Best) Charts We Made In This Long, Strange Year

    0

    Will The Debate Over $2,000 Stimulus Checks Help Democrats In Georgia?

    0
    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    May 31, 2025
    Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

    Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

    May 31, 2025
    Ontario Backs Down on Key Bill 5 Provisions, Echoes BC’s Mining Debate

    Ontario Backs Down on Key Bill 5 Provisions, Echoes BC’s Mining Debate

    May 30, 2025
    Appeals Court Grants Trump Temporary Reprieve on Tariffs, “TACO” Taunts Gain Steam

    Appeals Court Grants Trump Temporary Reprieve on Tariffs, “TACO” Taunts Gain Steam

    May 30, 2025

    Recent News

    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    NVIDIA Rallies After Strong Q1, AI Demand Outshines China Export Hit

    May 31, 2025
    Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

    Top 5 Canadian Mining Stocks This Week: Adyton Sparkles with 97 Percent Gain

    May 31, 2025
    Ontario Backs Down on Key Bill 5 Provisions, Echoes BC’s Mining Debate

    Ontario Backs Down on Key Bill 5 Provisions, Echoes BC’s Mining Debate

    May 30, 2025
    Appeals Court Grants Trump Temporary Reprieve on Tariffs, “TACO” Taunts Gain Steam

    Appeals Court Grants Trump Temporary Reprieve on Tariffs, “TACO” Taunts Gain Steam

    May 30, 2025

    Disclaimer: GlobalTrendsToday.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 globaltrendstoday.com | All Rights Reserved

    No Result
    View All Result
    • News
    • Economy
    • Investing
    • Stock
    • Editor’s Pick

    Copyright © 2025 globaltrendstoday.com | All Rights Reserved